- Hemlibra donation will provide prophylactic treatment to as many as 1,000 people with haemophilia A over five years in countries where there is little or no access to haemophilia treatment
- Donation will substantially increase the number of people receiving prophylactic treatment for haemophilia A through the World Federation of Hemophilia Humanitarian Aid Program
Roche today announced that it has joined the World Federation of Hemophilia (WFH) Humanitarian Aid Program, a landmark initiative leading the effort to change the lack of access to care and treatment for people with inherited bleeding disorders in developing countries. Together with Chugai and Genentech, members of the Roche Group, Roche’s commitment to the WFH Program consists of a donation of Hemlibra (emicizumab), a prophylactic treatment for haemophilia A, and funding to deliver the WFH Program’s integrated care development training to ensure that local infrastructure and medical expertise are available to optimise and appropriately use the donated Hemlibra.
The donation will provide prophylactic treatment with Hemlibra to as many as 1,000 people with haemophilia A in developing countries, over the course of five years, with a focus on high-need patients, such as people of all ages with factor VIII inhibitors and children without factor VIII inhibitors. Access to prophylactic treatment - the standard of care for haemophilia A to prevent bleeds in most of the developed world - is particularly restricted in developing countries, with limited resources reserved for emergency situations and acute bleeds.[1, 2] The WFH Humanitarian Aid Program currently provides prophylactic treatment to approximately 1,500 people with haemophilia A.
“Thanks to Roche’s donation, significantly more people with haemophilia A will be able to receive prophylaxis through the WFH Humanitarian Aid Program. Importantly, the donation will also provide a treatment option for people with haemophilia A with factor VIII inhibitors who previously had very limited or no treatment,” said Alain Weill, WFH President. “Increasing access to prophylactic treatments can make a profound difference in countries where haemophilia A remains underdiagnosed and untreated.”
Most people with haemophilia in developing countries receive no or inadequate treatment, which significantly affects their health, quality of life and life expectancy. Children with severe haemophilia in countries where there is no access to treatment often do not survive to adulthood.
“We are proud to join the WFH Humanitarian Aid Program, a landmark initiative leading the effort to change the lack of access to care and treatment for people with inherited bleeding disorders in developing countries,” said Bill Anderson, CEO Roche Pharmaceuticals. “Our partnership with the WFH reflects our commitment to the haemophilia community and to supporting rapid, broad and sustainable access to Hemlibra for all people with haemophilia A around the world who may benefit from this important treatment option.”
Hemlibra is the only prophylactic medicine that can be given subcutaneously and offers effective bleed control with dosing options as infrequent as every four weeks. Hemlibra has been studied in one of the largest pivotal clinical trial programmes in people with haemophilia A with and without factor VIII inhibitors, including four phase III studies (HAVEN 1, HAVEN 2, HAVEN 3 and HAVEN 4). Hemlibra has been approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people with haemophilia A with factor VIII inhibitors in over 50 countries worldwide. On 4 October 2018, Hemlibra was approved by the US Food and Drug Administration (FDA) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with haemophilia A without factor VIII inhibitors. On 1 February 2019, the EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in adults and children with severe haemophilia A without factor VIII inhibitors. Submissions to, and approvals by, other regulatory authorities around the world are ongoing.
To learn more about the WFH and the Humanitarian Aid Program visit www.wfh.org/en/humanitarian-aid-program.
About Hemlibra (emicizumab)
Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins required to activate the natural coagulation cascade and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once-weekly, every two weeks or every four weeks. Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab-kxwh), with kxwh as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the US Food and Drug Administration.
About Roche in haematology
For more than 20 years, Roche has been developing medicines that redefine treatment in haematology. Today, we are investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. In addition to approved medicines MabThera /Rituxan (rituximab), Gazyva /Gazyvaro (obinutuzumab), and Venclexta /Venclyxto? (venetoclax) in collaboration with AbbVie, Roche’s pipeline of investigational haematology medicines includes Tecentriq (atezolizumab), an anti-CD79b antibody drug conjugate (polatuzumab vedotin/RG7596) and a small molecule antagonist of MDM2 (idasanutlin/RG7388). Roche’s dedication to developing novel molecules in haematology expands beyond malignancy, with the development of Hemlibra (emicizumab), a bispecific monoclonal antibody for the treatment of haemophilia A.